Understanding COVID-19 transmission and health impacts in Malawi
Official title: COVID-19 Transmission and Morbidity in Malawi
Run by Boston University · NCT05973084 · Data updated 2026-11-12
This study is trying to understand why COVID-19 seems to affect people in Malawi less severely by looking at factors like immune responses and other health conditions in those who have the virus and their close contacts.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years to 75 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Boston University Academic / other |
| Locations | 2 sites (Boston, Massachusetts and 1 other locations) |
| Status | Recruiting |
| Started | January 17, 2023 |
| Main results expected | March 2028 |
| Study ends | March 2028 |
| Registry record updated | May 28, 2026 |
| Trial ID | NCT05973084 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 5 to 75 years with confirmed COVID-19 symptoms living in Blantyre, Malawi, and their household contacts.
✕Probably not a fit
Patients who have received a SARS-CoV-2 vaccine in the previous 3 months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the unique factors contributing to lower COVID-19 morbidity and mortality rates in Malawi compared to other regions. It will enroll symptomatic individuals with confirmed SARS-CoV-2 infections, their household contacts, and vaccinated individuals to assess the role of innate immune responses, malaria, and intestinal parasites in influencing susceptibility to infection and vaccine responses. Participants will be followed for up to 1.5 years to evaluate antibody responses and memory B cell longevity.
Why it matters
Potential benefit: If successful, this study could provide insights into protective immune factors that may inform COVID-19 prevention and treatment strategies in similar populations.
How similar studies have gone: While there have been studies on COVID-19 transmission and immunity, this specific focus on the interplay of malaria, intestinal parasites, and innate immunity in a sub-Saharan context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria Index Cases 1. Presents with symptoms of COVID-19 and has infection confirmed through RT-PCR or a rapid antigen test; 2. Aged 5 years to 75 years and plans to live in Blantyre, in the catchment area of the target research health centers for the following 6 months; 3. Confirmed SARS-CoV-2 infection and share a household with 1 or more individuals of eligible age; 4. Has not received a SARS-CoV-2 vaccine in the previous 3 months 5. Willingness to comply with study procedures and visits, and provides informed consent. Household Contacts of the Confirmed SARS-CoV-2 Case 1. Aged 5 years to 75 years and plans to live in Blantyre, in the catchment area of the target research health centers in the following 6 months; 2. Willingness to comply with study procedures and follow-up visits and provides informed consent. 3. Has not received a SARS-CoV-2 vaccine in the previous 3 months Vaccinees 1\) Aged 18 years to 75 years; 2) Willingness to receive the primary regimen of the AZ and/or JJ vaccines 2) Not in the other 2 cohorts; 4) Willingness to comply with study procedures and follow-up visits and provides informed consent. 5\) Has not received a prior dose of a SARS-CoV-2 vaccine Exclusion Criteria Index Cases 1. Conditions that precludes from adherence to the visit schedule; 2. 50% or more of household members decline to participate. 3. Pregnancy at the enrollment visit 4. Long term use of cotrimoxazole prophylaxis Household Contacts of the Confirmed SARS-CoV-2 Case 1. Conditions that preclude adherence to the visit schedule. 2. Participants with 2 consecutive negative SARS-CoV-2 RT-PCRs will be excluded from visits after M1. 3. Pregnancy at the enrollment visit 4. Long term use of cotrimoxazole prophylaxis Vaccinees 1. Conditions that preclude adherence to the visit schedule. 2. Pregnancy at the enrollment visit 3. Long term use of cotrimoxazole prophylaxis
Where it's running
-
Health center
Blantyre, Malawi Recruiting -
BU School of Public Health, Global Health Department
Boston, Massachusetts, United States Active not recruiting
Study contacts
- Principal investigator: Clarissa Valim, MD ScD — BU School of Public Health, Department of Global Health
- Study coordinator: Clarissa Valim, MD ScD
- Email: cvalim@bu.edu
- Phone: (617) 414-1260
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cardiovascular health five years after MIS-C in children
This study tests whether kids who had MIS-C still show cardiovascular differences five years later compared with healthy peers.
-
Remdesivir to prevent severe COVID-19 in kidney transplant patients
This study will try giving remdesivir around the time of transplant to see if it prevents severe COVID-19 in adults receiving a kidney transplant who are currently SARS‑CoV‑2 positive with no or mild symptoms.
-
2-HOBA to reduce persistent immune activation in Long COVID with POTS
This trial will test whether 2‑HOBA, a compound that scavenges harmful IsoLG-adducts, can reduce immune activation in adults with Long COVID who have POTS.
-
TFH-targeting COVID-19 booster vaccines with and without the 's3' component
This trial will test two experimental COVID-19 booster vaccines — one with an added 's3' component and one without — in healthy adults 40–64 to see if 's3' makes immune responses bigger, broader, and longer-lasting and to check safety.
-
Evaluating Baricitinib for Long COVID Symptoms
This study is testing if the medication baricitinib can help adults with Long COVID feel better physically and mentally compared to a placebo.
-
Study on influenza and COVID-19 effects in pregnant women in India
This study is testing how getting both COVID-19 and influenza affects pregnant women and their babies, while also looking at how vaccinations might help reduce risks during pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.